SecBot SecBot

CATX drug pipeline

$0.9200
−2.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±9.2%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1/2a
Time to marketAt least 3-5 years, assuming a successful End-of-Phase 2 meeting in Q1 2027, a Phase 3 trial initiated in 2027, positive readout, and subsequent FDA filing and review.

bamzireotide bamzireotide navoxetan Updated Nov 9

What to watch

Watch for the End-of-Phase 2 meeting outcome with the FDA in Q1 2027, which will determine the Phase 3 trial design and registration path. Positive FDA alignment could re-rate the stock from its deeply depressed levels, while negative feedback or a delayed timeline would add to the execution risks flagged by RBC. The company's ~$100M market cap and likely need for financing to fund a Phase 3 trial create additional overhang.

Bull case
  • Phase 1/2a data showed a 39% objective response rate and 75% 18-month PFS in 57 GEP-NET patients, comparing favorably to the approved beta-emitter Lutathera (roughly 13% ORR per the company's comparison).
  • Cohort 3 (24 mCi dose) showed a 47% ORR and 100% disease control rate, suggesting a dose-response relationship.
  • Clean safety profile across 68 patients: no dose-limiting toxicities, no treatment-related discontinuations, no Grade 4/5 adverse events.
Bear case
  • Phase 1/2a data come from a small, non-randomized study (n=57 for efficacy); results may not replicate in a larger Phase 3 trial.
  • RBC Capital downgraded the stock to Sector Perform from Outperform on October 26, 2026, cutting its price target from $14 to $4, citing execution risks around bamzireotide's competitive market, future Phase 3 conduct, and manufacturing build-out.
  • Major insider Lantheus (a 10%+ owner) sold roughly 500,000 shares in late August/early September 2026 at ~$3.10 per share.
● neutral
Impact
PhasePhase 1/2a
Time to marketVMT01 is in early-to-mid-stage clinical development (Phase 1/2a). Even under an accelerated path, a potential regulatory filing is likely several years away. The company first needs to complete dose escalation, determine the recommended Phase 2 dose, and then conduct a pivotal trial. Management has not provided a specific timeline for VMT01's registrational path.

VMT01 lapemelanotide zapixetar Updated Nov 10

What to watch

The SITC 2026 data (75% disease control rate, durable responses, no DLTs) is the most recent catalyst and has already been absorbed by the market. Watch for the company's next update on dose-escalation progress and any announcement regarding a registrational path for VMT01. The stock's sharp decline from $6.16 to $0.86 reflects broader pipeline skepticism, so positive VMT01 data alone may not be sufficient to reverse sentiment without a clear Phase 2/3 development plan. Monitor for additional combination cohort data and any regulatory guidance from the FDA on the path forward.

Bull case
  • Early efficacy signal is encouraging: 75% disease control rate at the 3.0 mCi monotherapy dose in heavily pre-treated melanoma patients (median 4 prior lines), with durable responses including one patient on study ~40 weeks, per SITC 2026 data presented November 6, 2026.
  • FDA granted Fast Track Designation for VMT01 in September 2024, which can expedite development and review.
  • Clinical collaboration with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab (Opdivo) provides validation and access to a leading immunotherapy.
Bear case
  • VMT01 is still in early Phase 1/2a with only 20 patients treated; the 75% disease control rate is from a small, non-randomized sample and may not replicate in larger trials.
  • The stock has fallen dramatically from its 52-week high of $6.16 to $0.86, reflecting investor disappointment with prior data readouts (stock fell ~17% in October 2024 after earlier Phase 1/2 data).
  • RBC Capital downgraded the stock from Outperform to Sector Perform on October 26, 2026, citing concerns about the pipeline.
● neutral
Impact
PhasePhase 1/2a
Time to marketPSV359 is in early clinical development (Phase 1/2a). Even under an accelerated path, a potential approval is likely several years away, contingent on successful dose-finding, expansion cohorts, and pivotal trial design and execution.

PSV359 [212Pb]PSV359 Updated Nov 10

What to watch

The next meaningful catalyst for PSV359 would be initial safety and efficacy data from the Phase 1/2a dose-escalation cohorts, but no specific readout date has been announced. Investors should also watch for updates on the Merck/Keytruda combination arm and any regulatory guidance on a potential pivotal path for the SFT Fast Track indication. The stock's dramatic decline from its 52-week high suggests the market has already priced in significant pipeline risk.

Bull case
  • FDA granted Fast Track designation for PSV359 in solitary fibrous tumors (SFTs), a rare cancer with limited treatment options, which can accelerate development and review
  • Clinical collaboration with Merck to evaluate PSV359 + Keytruda provides validation and resources from a top-tier pharma partner
  • The broader FAP-targeting field has significant scientific interest, and FAP is expressed across many solid tumor types, giving PSV359 a wide potential addressable market
Bear case
  • PSV359 is in very early Phase 1/2a testing with no efficacy data disclosed yet; the vast majority of Phase 1 oncology candidates fail to reach approval
  • The stock has fallen from a 52-week high of $6.16 to ~$0.86, reflecting deep investor skepticism about the broader pipeline and execution
  • Major insider selling by Lantheus Alpha Therapy (a 10% owner) in August-September 2026 at ~$3.10/share, well above the current price, signals weak confidence from a key strategic holder

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Oct 8, 2026PSV359Fast Track+8.1%−4.9%
Sep 1, 2024VMT01Fast Track−10.3%−1.2%